Very minimal wear to book or dust jacket. No writing/highlighting/folded pages. May contain a remainder mark. Not a former library book.

Technical and Biological Components of Marrow Transplantation presents up to date information on the scientific and technological advances that will extend and improve the clinical application of bone marrow transplantation.The book includes the latest...

Abdominal organ transplantation, specifically liver, kidney and pancreatic transplantation, has experienced a tremendous growth over the last two decades. With this growth comes a need for a general, standardized introduction for those healthcare...

Objective 1: For children who develop graft failure following cardiac transplantation retransplantation is often considered. While some centers have reported equivalent results for retransplantation as compared to primary transplantation this ...

Enterococci, especially vancomycin resistant enterococci (VRE), are increasing in prevalence in many hospitals in the United States. Patients undergoing liver transplantation are at particular risk for developing infection due to VRE. The effect of ...

Until recently HIV infection was considered as a contraindication for liver transplantation. A dramatic improvement in survival of HIV patients have been observed since the advent of new antiviral treatments against HIV including antiproteases. ...

BACKGROUND:Allogeneic bone marrow transplantation is an accepted therapeutic option for many hematologic immunologic and malignant diseases including chronic myelocytic leukemia and acute leukemia during or after first relapse (second remission). In ...

This study is a multicentre open-label prospective 2-arm phase IV study of tacrolimus in renal transplant recipients. Patients will be randomized to receive current clinical practice or to have a pre-transplant pharmacokinetic assessment of ...

A: Study groupFK506-MMF.Immunosupression protocol:Metylprednisolon 10 mg/kg intraoperatively ivFK506 Day 0 or 1 oraly (0 15 mg/kg/D in two doses).MMF max. dosage 30 mg/kg/D po day 0 through day 90 according to patient condition and therapeutic MMF ...

OBJECTIVES:- Determine if a one-year disease free survival of 40% and a day 200 transplant-related mortality of less than 25% can be achieved in patients with high-risk acute lymphoblastic leukemia in complete remission treated with a ...